Sigachi Industries Q1 FY27 Earnings Call Transcript Released

Sigachi Industries Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on August 13, 2026. The call featured insights from Managing Director and CEO Mr. Amit Raj Sinha, CFO Mr. O.S. Reddy, and Company Secretary Mr. Vivek Kumar.

During the call, the management discussed the company's performance and strategic initiatives for FY27, focusing on execution, innovation, and sustainable value creation. The company's cellulose-based excipient capacity stands at 18,000 metric tons per annum, with exports accounting for over 53.5% of production. A planned 12,000 metric ton per annum MCC capacity expansion at Dahej-2 is progressing on schedule, targeting commissioning by Q2 FY28, which will increase total capacity to 30,000 metric tons per annum. Additionally, an 1,800-ton Croscarmellose Sodium (CCS) facility at Dahej SEZ is under development to support higher-value excipient categories.

Sigachi launched HiCel SMCC Nutra, a specialized microcrystalline cellulose and magnesium aluminometasilicate blend for nutraceutical formulations, reinforcing its strategy to move up the value chain. The API business is also evolving, supporting a regulated market expansion.

Financially, for Q1 FY27, Sigachi reported total operating income of ₹121.27 crores, EBITDA of ₹16.5 crores (13.6% margin), and net profit of ₹8.14 crores (6.76% PAT margin). The MCC segment contributed ₹82.74 crores, while O&M and API segments recorded revenues of ₹13.06 crores and ₹21.68 crores, respectively.

The company reaffirmed its full-year revenue guidance of ₹650 crores to ₹675 crores and expects to achieve an EBITDA margin of 18% for the full year, with improvements expected in subsequent quarters due to increasing revenues and stable fixed costs.

Discussions also covered the MCC market demand and pricing, with average realization at ₹241.36 per kg in Q1 FY27, an increase from the previous quarter. The company addressed market share concerns, attributing any loss to temporary capacity shortfalls. The API business is expected to ramp up, with new molecules like Sparsentan and Bempedoic acid contributing to higher margins. The CCS market is estimated at $100 million globally, with average realizations between ₹1,200 to ₹1,500 per kg. Insurance claims related to a past incident are being processed, with an expected settlement by September 2026.

Capex plans include over ₹100 crores in FY27 and ₹150-200 crores in FY28, to be funded through internal accruals, borrowings, or potential equity raises.